Overview
Delcath Q3 revenue of $20.6 mln missed analyst expectations
Net income for Q3 was $0.8 mln, down from $1.9 mln last year
Company achieved positive adjusted EBITDA of $5.3 mln in Q3
Outlook
Delcath expects 2025 revenue between $83 mln and $85 mln
Company anticipates gross margins of 85% to 87% in 2025
Delcath projects positive adjusted EBITDA and cash flow each quarter of 2025
Result Drivers
HEPZATO KIT SALES - Revenue from HEPZATO KIT increased significantly to $19.3 mln from $10.0 mln in Q3 2024, driving overall revenue growth
R&D costs rise - R&D expenses were $8.0 million compared to $3.9 million last year
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Miss | $20.56 mln | $23.80 mln (7 Analysts) |
Q3 EPS | $0.02 | ||
Q3 Net Income | $830,000 | ||
Q3 Gross Profit | $17.93 mln | ||
Q3 Operating Expenses | $18.32 mln | ||
Q3 Operating Income | -$388,000 |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Delcath Systems Inc is $23.00, about 58.6% above its November 3 closing price of $9.52
The stock recently traded at 25 times the next 12-month earnings vs. a P/E of 36 three months ago
Press Release: ID:nBw7kWnsma
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)